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Toxoplasma gondii is an important pathogen which may cause fetal infection if primary infection. Our
previous studies have used human choriocarcinoma trophoblastic cells (BeWo cell line) as experimental
model of T. gondii infection involving placental microenvironment. This study aimed to examine the
effects of azithromycin and spiramycin against T. gondii infection in BeWo cells. Cells were treated with
different concentrations of the macrolide antibiotics and analyzed ﬁrst for cell viability using thiazolyl
blue tetrazole (MTT) assay. As cell viability was signiﬁcantly decreased with drug concentrations higher
than 400 mg/mL, the concentration range used in further experiments was from 50 to 400 mg/mL. The
number of infected cells and intracellular replication of T. gondii decreased after treatment with each
drug. The infection induced up-regulation of the macrophage migration inhibitory factor (MIF), which
was also enhanced in infected cells after treatment with azithromycin, but not with spiramycin. Analysis
of the cytokine proﬁle showed increase TNF-a, IL-10 and IL-4 production, but decreased IFN-g levels,
were detected in infected cells and treated with each drug. In conclusion, treatment of human tropho-
blastic BeWo cells with with azithromycin or spiramycin is able to control the infection and replication of
T. gondii. In addition, treatment with these macrolides, especially with azityromycin induces an
anti-inﬂammatory response and high MIF production, which can be important for the establishment and
maintenance of a viable pregnancy during T. gondii infection.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Toxoplasma gondii is an obligate intracellular protozoan that
infects a wide range of hosts. In humans, toxoplasmosis is associ-
ated with severe congenital defects when primary infection is
acquired during the ﬁrst trimester of pregnancy [1].e Embriologia, Instituto de
dia, Av. Pará, 1720, 38405-320
þ55 34 3218 2333.
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fu.br (J.R. Mineo), eloisa@
Elsevier OA license.Infection induces a Th1 response with production of proin-
ﬂammatory cytokines, such as IL-12 and IFN-g [2]. During preg-
nancy, however, there is an induction for type-2 immune response.
While a type-2 response is compatible with successful pregnancy,
a parasite-induced type-1 response may cause abortion by altering
the cytokine proﬁle of maternal-fetal interface. On the other hand,
the ability of pregnant host to downmodulate immune response
may interfere with mechanisms that normally control parasite
multiplication and can result in congenital infection [3].
Current toxoplasmosis of toxoplasmosis in pregnant is based on
the administration of spiramycin, which reaches high concentra-
tions in placental tissue, thus decreasing the risk of fetal trans-
mission [3]. However, if fetal infection occurs, a combination of
pyrimethamine with sulphadiazine is usually indicated [3]. Disad-
vantages of these drugs are related to limited effectiveness in para-
site clearance and lowpenetration in fetal tissues for spiramycin and
numerous toxicity problems for sulphadiazine-pyrimethamine, in
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pregnancy ﬁrst trimester [4]. Azithromycin is also a macrolide, with
advantages such as high oral bioavailability, rapid cell absorption,
and administration only once a day [5]. Azithromycin has better
pharmacokinetics and reaches greater tissue concentrations than
spiramycin, and has also shown a lower incidence of side effects,
especially hepatotoxic effects [4]. Our previous studies have shown
that azithromycin treatment in pregnant Calomys callosus females
was effective in inhibiting vertical transmission of T. gondii, sug-
gesting that it may be an alternative drug for the prevention of
congenital infection [6]. Macrolide antibiotics have anti-
inﬂammatory properties by modulating the production of proin-
ﬂammatorycytokines [7] that are preferentially produced inT. gondii
infection.
Clearly, placenta plays a major role in fetal protection, and
understanding this function is crucial for congenital toxoplasmosis
prevention. Previous studies have shown that placenta tropho-
blasts are directly involved in the pathogenesis of congenital
toxoplasmosis [8]. The role of trophoblast cells in the immunology
of pregnancy, especially in the presence of infection by intracellular
parasites, has been studied using well-established cell lines, such as
human BeWo choriocarcinoma cells [9]. These cells have morpho-
logical properties common to normal trophoblasts, including
secretion of cytokines as IL-4, IL-6, IL-8, IL-10, TNF-a and macro-
phage migration inhibitory factor (MIF) [10].
Even though macrolide treatment has been effective against
T. gondii in vitro and in vivo models [4e6], there are few data
involving its use in maternal-fetal interface and congenital toxo-
plasmosis. In this context, the present study aimed to verify the
effect of azithromycin and spiramycin against T. gondii infection in
human trophoblastic BeWo cells, by analyzing cell viability, rates of
infection and parasite replication, and cytokine proﬁles.
2. Materials and methods
2.1. Cell culture
BeWo cell line was obtained from American Type Culture Collection (ATCC,
Manassas, VA, USA) and cultured in RPMI-1640 medium (GIBCO, Paisley, UK), sup-
plemented with 25 mM HEPES, 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL
streptomycin (all reagents from Sigma Chemical Co., St Louis, MO, USA) and 10%
heat-inactivated fetal calf serum (complete medium) (Cultilab, Campinas, Brazil).
Cells were grown at 37 C with 5%CO2 in fully humidiﬁed air.
2.2. Parasite
Tachyzoites of T. gondii RH strain were obtained initially from peritoneal
exudates of previously infected Swiss mice [11] and maintained by serial passages in
BeWo cells in order to obtain in vitro tachyzoites for further infection experiments as
previously described [9]. Brieﬂy, tachyzoites were harvested by scraping off the cell
monolayer after 2e3 days of infection, passed through a 26-gauge needle to lyse any
remaining intact host cells, washed (720 g, 5min) in RPMImedium and the resulting
pellet was resuspended in complete medium. Parasites were stained with 0.4%
Trypan blue and counted in a hemocytometric chamber for infection experiments.
2.3. Antibiotics
Macrolides azithromycin (Biofarma, Uberlândia, Brazil) and spiramycin (Sigma
Chemical Co.) were dissolved in sterile water to a concentration of 3000 mg/mL
(stock solution). Stock solution was freshly reconstituted and different macrolide
concentrations were used for cell treatment.
2.4. MTT assay
Cell viability was evaluated by colorimetric assay using thiazolyl blue tetrazole
(MTT) assay (Sigma Chemical Co.) as previously described [12]. BeWo cells were
cultured in 96-well plates (5104 cells/200 mL/well) in completemedium for 24 h at
37 C and 5%CO2. Cells were treated with different concentrations of azithromycin or
spiramycin, and after 24 h of treatment, cells were pulsed withMTTat 0.5 mg/mL 4 h
prior to the end of the culture. Formazan particles were solubilized in 10% sodium
dodecyl sulfate (SDS) and 50% N, N-dimethyl formamide. The optical density was
determined at 570 nm in a plate reader (Titertek Multiskan Plus, Flow Laboratories,Mc Lean, USA). Results were expressed as percentage of viable cells in relation to
controls (100% of cell viability).
2.5. Infection and intracellular replication of parasite
BeWo cells were cultured on 13-mm round glass coverslips into 24-well plates
(5  104 cells/200 mL/well) in complete medium for 24 h at 37 C and 5%CO2. Cells
were washed with medium and infected with T. gondii tachyzoites (host cell:ta-
chyzoites, 1:3) in complete medium. After 24 h, cells were washed again with
medium and incubated with 200 mL/well of an antibiotic solution containing azi-
thromycin or spiramycin in different concentrations (50, 100, 200 and 400 mg/mL) at
37 C and 5%CO2 for 24 h. As controls, non-infected non-treated cells (control) or
infected non-treated cells (Tg control) were kept with medium alone. After 24 h,
cell-free supernatants were collected and stored at70 C for further cytokine assay.
Cells were then washed with sterile phosphate-buffered saline (PBS), ﬁxed in 10%
phosphate-buffered formalin for 2 h and stained with 1% toluidine blue (Sigma
Chemical Co.) for 3 s. Coverslips were mounted on glass slides and cells were
examined under a light microscope with regards to the index of infection
(percentage of infected cells per 200 examined cells) and parasite intracellular
replication (number of parasites per cell in 200 infected cells) [9]. Three indepen-
dent experiments were performed in triplicate for each condition.
2.6. Cytokine measurement in T. gondii-infected BeWo cells
2.6.1. Measurement of MIF by enzyme-linked immunosorbent assay (ELISA)
MIF was measured using a sandwich ELISA according to the manufacturer’s
instructions (R&D Systems, Minneapolis, MN, USA). Brieﬂy, plates were coated
overnight with capture monoclonal anti-human MIF antibody, blocked and incu-
bated with samples in duplicate for 2 h at room temperature. After washing, plates
were incubated with biotinylated polyclonal anti-human MIF antibody for 2 h at
room temperature. The assay was developed with streptavidin-horseradish perox-
idase (Zymed, San Francisco, CA, USA) and revealed with 3,30 ,5,50-tetrame-
thylbenzidine (TMB, Zymed). MIF concentration was determined by extrapolation
from a standard curve obtained from known concentrations of rMIF cytokine
standard. The assay sensitivity was 18 pg/mL. Intra- and inter-assay coefﬁcients of
variation were 3.86% and 9.14%, respectively.
2.6.2. Measurement of Th1/Th2 cytokines by cytometric bead array (CBA)
Human cytokines (IL-2, IL-4, IL-5, IL-10, IFN-g and TNF-a) were measured using
cytometric bead array (CBA; BD Biosciences, San Jose, CA, USA) according to the
manufacturer’s instructions. Brieﬂy, samples were mixed with mix of each human
cytokine capture bead and incubatedwith PE-conjugated anti-human IL-2, IL-4, IL-5,
IL-10, IFN-g and TNF-a antibodies for 3 h at room temperature, protected from light.
After centrifugation, supernatants were carefully aspirated and discarded. The bead
pellets were resuspended and samples were analyzed under BD ﬂow cytometry
(FACSCalibur, BD Company, San Diego, CA, USA). Data were analyzed using
specialized software BD Cell Quest and CBA software. Results are presented as
mean ﬂuorescence intensity (MFI) of all cytokines.
2.7. Data analysis
Statistical analyses were carried out using GraphPad Prism 5.0 (GraphPad
Software Inc., San Diego, USA). Datawere expressed as mean standard deviation of
three independent experiments performed in triplicate. Data comparisons in rela-
tion to control were performed by one-way ANOVA and Dunnett post hoc test.
Comparisons of data between treated cells with azitromycin and spiramycin were
performed using the Student’s t test. Differences were considered statistically
signiﬁcant if a P value < 0.05 was achieved.3. Results
3.1. BeWo cells maintain viability after treatment with azitromycin
or spiramycin
The number of viable BeWo cells after treatment with different
concentrations of azithromycin or spiramycin was evaluated using
the MTT assay (Fig. 1). No signiﬁcant difference in cell viability was
observed when BeWo cells were treated with azithromycin in
concentrations from 50 to 400 mg/mL compared to non-treated
controls, whereas higher concentrations (600 and 800 mg/mL)
exhibited signiﬁcant reduction in cell viability (Fig. 1A). For spi-
ramycin, viability of BeWo cells decreased only at the highest
concentration (800 mg/mL) compared to non-treated controls
(P < 0.05) (Fig. 1B). Based on these observations, the subsequent
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Fig. 1. Cell viability of BeWo cells after incubation with increasing concentrations of azithromycin (A) and spiramycin (B). Cells were cultured in 96-well plates (5  104 cells/200 mL/
well) and after 24 h were treated with different concentrations of azithromycin or spiramycin or kept with medium (control) at 37 C and 5%CO2. Viable cell numbers were analyzed
using thiazolyl blue tetrazole (MTT) after 24 h treatment. Data are expressed as the percentage of viable cells in relation to the control (mean  S.D.) and are representative of two
independent experiments in triplicate. *P < 0.05 (ANOVA and Dunnett multiple comparison post-test).
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range from 50 to 400 mg/mL.
3.2. Macrolides decrease infection with T. gondii in BeWo cells
In order to verify if the drugs had effect on T. gondii control in
BeWo cells, indexes of infection and parasite intracellular replica-
tion were evaluated (Fig. 2). Cell treatment with either azi-
thromycin or spiramycin signiﬁcantly reduced the infection index
in BeWo cells, showing a dose-response effect rather than the other
way round, with the higher reduction seen for the highest drug
concentration (Fig. 2A). Comparison of the treatments showed
a higher infection index in cells treated with spiramycin at
concentrations of 50 and 400 mg/mL (P < 0.05) (Fig. 2A). Regarding
the index of parasite replication, cell treatment with either dose of
azithromycin signiﬁcantly decreased the number of intracellular
parasites compared with non-treated cells (Fig. 2B). Comparison
between the drugs showed a higher number of intracellular para-
sites when BeWo cells were treated with spiramycin in the lowest
concentrations (50 and 100 mg/mL) (P < 0.05) (Fig. 2B).
The effect of drugs in parasite replication was also evaluated by
T. gondii growth inhibition as shown in Table 1. The treatment with
increasing concentrations of azithromycin resulted in signiﬁcant
inhibition of tachyzoite growth from 13 to 41% (P < 0.05). The
inhibitory effect of spiramycin on T. gondii growth was observed
only at concentrations of 200 and 400 mg/mL, with inhibition of 24%
and 31%, respectively. Photomicrographs of BeWo cells showed
a greater number of T. gondii infected cells in those that were not
treated (Fig. 3A) as compared to those treated with azithromycin
(Fig. 3B,C) or spiramycin (Fig. 3D).
3.3. MIF production is enhanced in T. gondii-infected BeWo cells
after azitromycin treatment
Non-infected BeWo cells showed signiﬁcant increase in MIF
production after treatment with azithromycin (100 and 200 mg/mL)
and with any concentration of spiramycin as compared with non-
treated control (Fig. 4A). Comparison of the treatments showed
higher MIF production for spiramycin than azitromycin only in the
highest concentration (400 mg/mL) (P < 0.05) (Fig. 4A). MIF secre-
tion was increased after T. gondii infection and treatment withazithromycin in any concentration analyzed (P < 0.05) (Fig. 4B). In
contrast, no signiﬁcant differences were observed when cells were
infected and treated with spiramycin for any concentration
(Fig. 4B). Also, T. gondii infection increased MIF production in BeWo
cells (Tg control) compared with non-infected control (P < 0.05).
3.4. Macrolide treatment in T. gondii-infected BeWo cells induces
decreased IFN-g production
Cytokine proﬁle was evaluated in culture supernatants from
BeWo cells infected or not with T. gondii after treatment with azi-
thromycin or spiramycin in different concentrations (Fig. 5). Treat-
ment of non-infected BeWo cells with any concentrations of
azithromycin or spiramycin (50e400 mg/mL) did not alter the TNF-a
or IFN-g production when compared to non-treated control cells
(Fig. 5A,C). In contrast, treatment of infected cells with azithromycin
(100 and 200 mg/mL) or spiramycin (400 mg/mL) slightly increased
TNF-a production compared with non-treated infected cells
(P < 0.05) (Fig. 5B). Comparison of the treatments showed a signif-
icantly higher production of TNF-a in cells treated with 200 mg/mL
of azithromycin or 400 mg/mL of spiramycin (Fig. 5B). Interestingly,
both macrolides induced decreased IFN-g production in infected
BeWo cells compared to non-treated infected cells, irrespective of
the drug concentration used (P< 0.05) (Fig. 5D), and the comparison
of the treatments showed no signiﬁcant differences. In addition, no
change was observed in IL-2 production from BeWo cells treated
with either drug compared with non-treated control or from
infected treated BeWo cells compared with non-treated infected
control (data not shown).
3.5. Macrolide treatment in T. gondii-infected BeWo cells induces an
anti-inﬂammatory response
Analyses of the anti-inﬂammatory cytokine levels showed that
IL-10 levels decreased in non-infected cells and treated with azi-
thromycin at 200 and 400 mg/mL, as well as in cells treated with
spiramycin at any concentration (P < 0.05) (Fig. 5E). After infection,
azithromycin at 50 and 400 mg/mL and spiramycin at 100 mg/mL
signiﬁcantly increased the IL-10 production compared to non-
treated infected control (Fig. 5F), and no signiﬁcant differences
were found between the treatments. IL-4 production was not
Table 1
T. gondii tachyzoite growth inhibition in BeWo cells infected and treated with
increasing concentrations of azithromycin or spiramycin.
Drugs Intracellular
replication indexa
Inhibition of
tachyzoite
growth (%)
Control (without
treatment)
551.2  19.7 e
Azitromycin
(mg/mL)
50 479.4  24.4* 13.0
100 418.8  46.1* 24.0
200 447.6  22.9* 18.9
400 326.5  22.1* 40.8
Spiramycin
(mg/mL)
50 544.8  22.3# 1.2
100 514.2  19.2# 6.7
200 419.3  28.5* 23.9
400 378.0  25.0* 31.4
*Statistically signiﬁcant differences in relation to control (P < 0.05); #Statistically
signiﬁcant differences when comparing azithromycin and spiramycin concentra-
tions (P < 0.05).
a Index of intracellular replication was calculated as the number of parasites/200
infected cells and expressed in mean SEM from three independent experiments in
triplicate.
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Fig. 2. Toxoplasma gondii infection and intracellular replication in BeWo cells without
andwithmacrolide treatments. Cellswere culturedon coverslips into 24-well plates and
infected with T. gondii (host cell:tachyzoites, 1:3) for 24 h. Infected cells were treated
with increasing concentrations of azithromycin or spiramycin or medium alone (Tg
control). After 24 h, cells were washed, ﬁxed, stained with toluidine blue and analyzed.
(A), percentage of infected cells per 200 examined cells; (B), number of parasites per cell
in 200 infected cells. Data are expressed as mean  S.D and are representative of three
independent experiments in triplicate. *Comparison between infected/treated cells and
control for each treatment condition (ANOVA and Dunnett multiple comparison post-
test, P < 0.05). #Comparison between BeWo cells treated with azithromycin and spi-
ramycin in each drug concentration (Student’s t test, P < 0.05).
P.S. Franco et al. / Placenta 32 (2011) 838e844 841changed when non-infected cells were treated with either drug
(Fig. 5G), but when infected cells were treated, it was observed an
increase of IL-4 at 100, 200 and 400 mg/mL of azithromycin and in
all concentrations of spiramycin (P < 0.05) (Fig. 5H). In addition,
higher IL-4 levels were detected when infected cells were treated
with spiramycin at 50 mg/mL compared to ones treated with azi-
thromycin at the same concentration (Fig. 5H). No signiﬁcant
difference in IL-5 productionwas observed when cells were treated
with each drug irrespective of whether the cells were infected or
not (data no shown).
4. Discussion
Although the biology and physiology of T. gondii is widely
investigated, the current therapies for toxoplasmosis present still
limited efﬁcacy due to their substantial side effects as high
toxicity and/or drug resistance [5]. Macrolides are a well-established class of antimicrobial agents that play an important
role in the management of infectious diseases [13]. However,
previous studies comparing azithromycin and spiramycin toxicity
showed that they displayed inhibitory activity against T. gondii
only at concentrations that were toxic to host cells and therefore
were considered unsuitable for the therapy [14]. Hepatotoxic
effects of macrolides were compared and demonstrated that
azithromycin was found to be less toxic for a cultured human
liver cell line [15]. In endothelial cell line and ﬁbroblasts, azi-
thromycin had toxic effect for endothelial cell in concentration
above of 40 mg/L and for ﬁbroblasts above of 80 mg/L [16],
showing that cytotoxicity is related to cell types. In the present
study, BeWo cells showed high viability even in the presence of
5e10-fold increased concentrations of azithromycin, making
possible to use this trophoblast cell line as in vitro models to
evaluate therapies for T. gondii infection.
Treatment with azithromycin and spiramycin reduced T. gondii
infection and parasite replication in BeWo cells, especially when
azithromycin was used. In vitro assays showed that azithromycin
was the most active macrolide against T. gondii and was the only
that demonstrated a prolonged inhibitory activity against the
parasite after removal of drug [14]. It was also demonstrated that
the anti-T. gondii effect of azithromycin is due to its ability to
effectively inhibit the replication of the parasite [17]. It is known
that some macrolides, such as azithromycin, penetrate and accu-
mulate more readily than others in phagocytes [18] and human
ﬁbroblasts [19]. This may also be true for trophoblast cell types like
BeWo cells and may account for the greater inhibitory activity of
azithromycin against intracellular T. gondii growth.
Proinﬂammatory cytokines and mediators play a central role in
initiating and propagating the acute and chronic inﬂammatory
processes. There is evidence that macrolide antibiotics exerted
their anti-inﬂammatory effects through modulation of inﬂamma-
tory cascade [20]. In the present study, we showed that MIF was
spontaneously secreted by BeWo cells, and when cells were treated
with azithromycin or spiramycin, MIF production was increased.
After T. gondii infection, however, only treatment with azi-
thromycin was able to upregulate MIF production, indicating
a possible interaction between azithromycin and MIF in the control
of T. gondii infection. MIF is considered a major regulator of
inﬂammatory responses, since it is critical for host defense against
Fig. 3. Photomicrographs of BeWo cells after infection Toxoplasma gondii and treatment with azithromycin or spiramycin. Arrows indicate parasites inside the parasitophorous
vacuoles. Note higher number of infected cells in non-treated cells (A) and the lower number of infected cells after treatment with 100 mg/mL (B) or 400 mg/mL (C) of azithromycin,
and 400 mg/mL (D) of spiramycin. Toluidine blue staining. Bar scale: 33 mm.
P.S. Franco et al. / Placenta 32 (2011) 838e844842intracellular parasites as T. gondii [21]. In a previous study, MIF
production and secretion by human villous explants were strongly
associated with stimulation by soluble Toxoplasma antigen (STAg)
[22]. Recently, our group demonstrated that MIF was up-regulated
in ﬁrst-trimester explants, and is important to T. gondii infection
control; whereas lack of MIF up-regulation in third-trimester
placentas may be involved in higher susceptibility to infection at
this gestational age [23].Co
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Fig. 5. Cytokine production by BeWo cells infected or not with Toxoplasma gondii (Tg) after treatment with different concentrations of azithromycin or spiramycin. Cell-free
supernatants were collected after 24 h of treatment and the production of Th1 and Th2 cytokines was measurement by Cytometric Beads Array (CBA). Production of TNF-a (A,
B), IFN-g (C, D), IL-10 (E, F) and IL-4 (G, H) by BeWo cells non-infected and treated with azithromycin or spiramycin (A, C, E, G) or infected and treated with each drug (B, D, F, H).
Data are expressed as mean  S.D. and representative of two independent experiments in triplicate. *Comparison between treated and control or infected/treated cells and Tg
control for each treatment condition (ANOVA and Dunnett multiple comparison post-test P < 0.05). #Comparison between BeWo cells treated with azithromycin and spiramycin in
each drug concentration (Student’s t test, P < 0.05).
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they are important modulators of innate and adaptive elements of
cell mediated immunity [24]. IL-4, IL-10 and IL-13 have been
frequently shown to display biological activities opposed to those
induced by IFN-g and that IL-10 antagonizes the expression of
various genes and functions induced by IFN-g [25]. Thus, the
increased levels of IL-4 and IL-10 which we detected in infected
BeWo cells treated with azithromycin or spiramycin may be
involved in the decrease IFN-g production.
Acute T. gondii infection during gestation may disrupt the
maternal-fetal immunological balance in favor of anti-parasitic
proinﬂammatory abortogenic cytokines, such as IFN-g and TNF-a,
which are reported to be potentially deleterious for conception [26].
However, inT. gondii-infected pregnantmice, TNF-adid not function
as an abortogenic cytokine [26]. Furthermore, it was demonstrated
that TNF-a stimulates the indoleamine 2,3-dioxygenase expression,
an enzyme that catalyzes the initial and rate-limiting step of tryp-
tophan catabolism, thus inhibiting tachyzoite replication within
human ﬁbroblast lineage cells [27]. Our results showed not only
a decrease in IFN-g levels but also a slightly increased on TNF-
a production, which could be crucial to maintain pregnancy.
Despite of IFN-g is the pivotal mediator that induces anti-
T. gondii effector mechanisms [28], BeWo cells were unable to
control replication of T. gondii, even in the presence of exogenous
IFN-g [9]. Moreover, IL-10 plays an important role in the balance
between protective immunity and the development of immune
pathology. Treatment with exogenous IL-10 induced considerable
augmentation in both T. gondii intracellular replication and index of
infection in BeWo cells, showing that the protector immune
response proﬁle seen typically in several host organisms involves
the presence of inﬂammatory cytokines, such as IFN-g and IL-12
[29]. BeWo cells were susceptible to T. gondii infection when anti-
inﬂammatory cytokines, such as IL-10 and TGF-b1 are involved,
supporting the hypothesis that these cytokines may also facilitate
parasite transmission for fetal tissues [9]. In this study, increased IL-
10 levels after macrolide treatment did not inﬂuenced in the
T. gondii intracellular replication and index of infection in BeWocells, indicating that T. gondii seems to be controlled by macrolide
treatment and possibly by TNF-a.
In conclusion, the present study demonstrated that treatment of
human trophoblastic (BeWo) cells with azithromycin or spiramycin
is able to control T. gondii infection and replication. The macrolide
treatment induces an anti-inﬂammatory immune response, with
increased MIF, IL-4 and IL-10 levels, which could be important for
the maintenance of a viable pregnancy as well as to control the
infection. Further studies should be conducted to compare the
effect of both drugs in human placental explants, as well as in
congenital toxoplasmosis experimental models in vivo using cyto-
kine knock-out mice.Acknowledgments
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